Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
Accession Number
DB14385
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Description

Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is a vaccine.

Synonyms
Not Available
Active Moieties
NameKindUNIICASInChI Key
Influenza b virus b/brisbane/60/2008 antigen (formaldehyde inactivated)unknownW45Z4CJE2JNot AvailableNot applicable
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
FluarixInfluenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + INFLUENZA A VIRUS A/BRISBANE/59/2007(H1N1) HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) (15 ug/0.5mL) + INFLUENZA A VIRUS A/URUGUAY/716/2007(H3N2) HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2009-07-162009-07-15Us
Fluarix 2010/2011Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/california/7/2009 x-181 (h1n1) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza a virus a/victoria/210/2009 x-187 (h3n2) hemagglutinin antigen (formaldehyde inactivated) (15 ug/0.5mL)SuspensionIntramuscularGlaxoSmithKline Biologicals SA2010-08-092010-08-02Us
Categories
UNII
166D8OWM7B
CAS number
Not Available

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 2-Methoxyethanol.
25-desacetylrifapentineThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 25-desacetylrifapentine.
6-Deoxyerythronolide BThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Acetylsalicylic acid.
ActeosideThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Influenza b virus b/brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionFlu caused by Influenza / Influenza Vaccines / Seasonal Influenza1
1CompletedPreventionFlu caused by Influenza / Influenzae Disease1
1Enrolling by InvitationPreventionPlasmodium Infections1
1, 2Active Not RecruitingTreatmentFlu caused by Influenza1
2CompletedPreventionFlu caused by Influenza11
2CompletedPreventionFlu caused by Influenza / Influenza Infection2
2CompletedPreventionFlu caused by Influenza / Influenza Vaccines2
2CompletedPreventionFlu caused by Influenza / Influenza, Human1
2CompletedPreventionFlu caused by Influenza / Pandemic Flu1
2CompletedPreventionHealthy Volunteers1
2TerminatedPreventionFlu caused by Influenza / Influenza Disease1
2, 3WithdrawnPreventionHuman Immunodeficiency Virus (HIV) / Influenza, Human / Plasmodium Infections / Poliomyelitis / Tetanus1
3CompletedPreventionAcellular Pertussis / Diphtheria / Flu caused by Influenza / Pertussis / Tetanus1
3CompletedPreventionFlu caused by Influenza7
3CompletedPreventionFlu caused by Influenza / Influenza A Virus, H1N1 Subtype / Influenza Infection1
3CompletedPreventionFlu caused by Influenza / Influenza Disease / Influenza Vaccines1
3CompletedPreventionFlu caused by Influenza / Influenza Vaccines1
3CompletedPreventionFlu caused by Influenza / Seasonal Influenza1
3CompletedPreventionMeningococcal Infections1
4Active Not RecruitingPreventionFlu caused by Influenza1
4CompletedOtherAsthma Bronchial / Influenza Vaccines in Asthma Populations1
4CompletedPreventionFlu caused by Influenza4
4CompletedPreventionFlu caused by Influenza / Influenza Infection1
4RecruitingPreventionFlu caused by Influenza / Influenza immunisation1
Not AvailableCompletedNot AvailableFlu caused by Influenza1
Not AvailableCompletedBasic ScienceImmune Response1
Not AvailableCompletedPreventionInfluenza, Human2
Not AvailableRecruitingBasic ScienceAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV)1
Not AvailableRecruitingBasic ScienceInfluenza, Human1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
SuspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on July 05, 2018 12:02 / Updated on May 01, 2019 11:59